Funding from Netherlands-based Esperante, Northstar Ventures' Finance for Business North East Accelerator Fund and the Technology Strategy Board (TSB) mean the firm can develop its urine test for cancer detection. UroSens will work with over 1,2000 ...
The company has received a £500,000 investment from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures' Finance for Business North East Accelerator Fund, and existing investors. And a further grant of ...
It has received £0.5 million investment from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures' Finance for Business North East Accelerator Fund, and existing investors and entered into clinical trials ...
The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures' Finance for Business North East Accelerator Fund, and existing investors. In addition to the £0.5M investment ...